





Paxton Provitera is an accomplished U.S. biomedical engineer with a PhD in Physiology and Biophysics. With a solid foundation in both biomedical engineering and advanced physiological sciences, he has made significant contributions to the field. As the R&D Project Manager at Pall Medical for 15 years, Paxton played a pivotal role in designing the selective filter for concentrating peripheral blood mononuclear cells. This innovation has been a key development in autologous cell therapy, particularly for the treatment of critical ischemia in lower limbs and diabetic foot ulcers.
Currently, Paxton serves as the leader of PAX Advanced Therapies, a company dedicated to the development of next-generation filtration and cell separation systems. His work focuses on tackling complex biomedical challenges and advancing cutting-edge methods that address the increasing demands of modern medicine and therapeutic interventions. Through his expertise and leadership, Paxton is contributing to the development of innovative technologies that have the potential to revolutionize treatments for a wide range of medical conditions.
Proven project manager, scientist, medical device marketer and salesman with a recent focus on Animal/Human health. Experienced with USDA/FDA/EMA regulatory requirements and clinical trials required to work through the stages of a product from its conception to regulated product launch.
Key Accomplishments
• Generated over $1 million in annual revenue within 2 years of initial product launch within animal health
• Executed distributor agreements for animal health division of Pall with major global veterinary distribution partners generating over $2 million in annual revenue
• Tackled a number of complex global supply issues and structural costs resulting in delivery of over $500K in open orders in the last quarter of the FY’14
• Presented lectures, training and education globally (US, Asia, Europe, South America) generating 50% increase in sales from the previous year 2013


A seasoned, results-driven Global Sales & Marketing Executive with a background in aesthetics, medical devices, diagnostic testing, capital equipment, product manufacturing, pharmaceuticals, consumer electronics, technology and healthcare.
Derek’s most recent senior leadership roles include SVP, Global Sales and Marketing for Innova Medical Group/Pasaca Capital, Inc. (Private Equity), heading their medical device division, VP of US Sales at Aesthetics Biomedical, heading the commercialization/launch of Vivace® Ultra, and Director of US Surgical Sales at Cynosure, where he co-created their surgical division and was responsible for the launch and commercial success of MyEllevate®. Prior to Cynosure, Derek was Director of Business Development for Fresenius Medical Care and responsible for the growth of $400M in treatment revenue, through strategic M&A, Nephrologist joint ventures, and dialysis clinic real-estate development.
Previously, Derek spent nearly a decade at Allergan Aesthetics (Abbvie) in various sales & marketing leadership roles; strategically building and launching new aesthetic markets and powerhouse brands to top national success including Botox® Cosmetic, Juvederm® XC, Kybella®, Juvederm® Voluma, Latisse®, and the Allē Patient Loyalty Program.
Derek also had a successful career at Pfizer-Wyeth, Merck & Co. Inc., and Marriott International.
Currently, he serves as a Board Member for RealSelf’s Industry Insiders and on the Fundraising Committee for Kidsave, an organization with a mission to help place foster children with their forever families.
With over 25 years of top-tier management experience, Rich has honed his expertise in financial and business analysis, as well as a robust networking acumen. As part of a dynamic team, his mission is to drive innovative solutions that align with his core competencies of transforming challenges into strategic opportunities. His career is marked by a dedication to fostering growth and operational excellence. His leadership is guided by a commitment to integrity and collaboration, ensuring that the company continues to thrive in a competitive landscape.


Ray Thomas is an experienced finance and operations professional with a strong background in strategic planning, financial analysis, and organizational efficiency. With over two decades of experience leading teams across real estate, technology, and innovation, he brings a disciplined, data-driven approach to optimizing performance and enabling scalable growth.
Ray’s expertise includes financial modeling, resource planning, and process development that strengthen decision-making and operational execution. At Pax Advanced Therapies, he applies his analytical mindset and collaborative leadership style to advance the company’s mission and support continuous improvement. He is known for his adaptability and commitment to operational excellence.

Paxton Provitera is an accomplished U.S. biomedical engineer with a PhD in Physiology and Biophysics. With a solid foundation in both biomedical engineering and advanced physiological sciences, he has made significant contributions to the field. As the R&D Project Manager at Pall Medical for 15 years, Paxton played a pivotal role in designing the selective filter for concentrating peripheral blood mononuclear cells. This innovation has been a key development in autologous cell therapy, particularly for the treatment of critical ischemia in lower limbs and diabetic foot ulcers.
Currently, Paxton serves as the leader of PAX Advanced Therapies, a company dedicated to the development of next-generation filtration and cell separation systems. His work focuses on tackling complex biomedical challenges and advancing cutting-edge methods that address the increasing demands of modern medicine and therapeutic interventions. Through his expertise and leadership, Paxton is contributing to the development of innovative technologies that have the potential to revolutionize treatments for a wide range of medical conditions.
© 2025, PAX Advanced Therapies. All Rights Reserved.